No Prescription |
 |
 | ||
|
Senzia Avandia |
|
| ||
No Prescription » Prescription Drugs 14 » Senzia Avandia Rosiglitazone is an anti-diabetic drug (thiazolidinedione-type also called "glitazones") used with a proper diet and exercise program to control high blood sugar in patients with type 2 diabetes (non-insulin-dependent diabetes). Rosiglitazone works by helping to restore your body's proper response to insulin thereby lowering your blood sugar. Controlling high blood sugar helps prevent kidney damage blindness nerve problems loss of limbs and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Buy Senzia Avandia and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About Senzia Avandia: Product Type: Prescription Drugs 14 Senzia ( Avandia Generic Rosiglitazone ) Senzia (Avandia Generic Rosiglitazone) Avandia Generic Rosiglitazone 8mg Avandia Generic Rosiglitazone Senzia
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
